{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T21:55:10Z","timestamp":1793656510476,"version":"4.5.1"},"reference-count":46,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T00:00:00Z","timestamp":1779148800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["24K19198"],"award-info":[{"award-number":["24K19198"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Transplantation and Cellular Therapy"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.jtct.2026.05.028","type":"journal-article","created":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T16:32:43Z","timestamp":1779381163000},"page":"954.e1-954.e11","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Prolonged Cytokine Release Syndrome is Associated with Hypofibrinogenemia after CD19-Directed CAR T-Cell Therapy in Adult Patients with Relapsed\/Refractory Lymphoma"],"prefix":"10.1016","volume":"32","author":[{"ORCID":"https:\/\/orcid.org\/0009-0006-9495-6231","authenticated-orcid":false,"given":"Seiya","family":"Bamba","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9381-0421","authenticated-orcid":false,"given":"Tomoyasu","family":"Jo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6373-3442","authenticated-orcid":false,"given":"Toshio","family":"Kitawaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-6508-9432","authenticated-orcid":false,"given":"Noriyoshi","family":"Yoshinaga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Sakamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6704-3633","authenticated-orcid":false,"given":"Junya","family":"Kanda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4171-2162","authenticated-orcid":false,"given":"Momoko","family":"Nishikori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kouhei","family":"Yamashita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8886-6145","authenticated-orcid":false,"given":"Miki","family":"Nagao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akifumi","family":"Takaori-Kondo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuyuki","family":"Arai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jtct.2026.05.028_bib0001","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1111\/bjh.15412","article-title":"How I manage patients with relapsed\/refractory diffuse large B cell lymphoma","volume":"182","author":"Gisselbrecht","year":"2018","journal-title":"Br J Haematol"},{"key":"10.1016\/j.jtct.2026.05.028_bib0002","doi-asserted-by":"crossref","first-page":"1800","DOI":"10.1182\/blood-2017-03-769620","article-title":"Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study","volume":"130","author":"Crump","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2026.05.028_bib0003","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1056\/NEJMoa1709866","article-title":"Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia","volume":"378","author":"Maude","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtct.2026.05.028_bib0004","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","article-title":"ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells","volume":"25","author":"Lee","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jtct.2026.05.028_bib0005","doi-asserted-by":"crossref","first-page":"e123","DOI":"10.1016\/j.bbmt.2018.12.756","article-title":"Cytokine release syndrome with chimeric antigen receptor T cell therapy","volume":"25","author":"Frey","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jtct.2026.05.028_bib0006","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.577027","article-title":"Cytokines in CAR T cell-associated neurotoxicity","volume":"11","author":"Gust","year":"2020","journal-title":"Front Immunol"},{"key":"10.1016\/j.jtct.2026.05.028_bib0007","doi-asserted-by":"crossref","first-page":"297","DOI":"10.3324\/haematol.2019.229781","article-title":"Management of adults and children undergoing chimeric antigen receptor T-cell therapy: best practice recommendations of the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE)","volume":"105","author":"Yakoub-Agha","year":"2020","journal-title":"Haematologica"},{"key":"10.1016\/j.jtct.2026.05.028_bib0008","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1111\/bjh.18504","article-title":"Decreased serum phosphate levels are a useful biomarker to predict occurrence and severity of cytokine release syndrome in chimeric antigen receptor T-cell therapy","volume":"200","author":"Nakamura","year":"2023","journal-title":"Br J Haematol"},{"key":"10.1016\/j.jtct.2026.05.028_bib0009","article-title":"Low reticulocyte count at infusion is a risk factor for high-grade cytokine release syndrome in chimeric antigen receptor T cell therapy","author":"Tashiro","year":"2025","journal-title":"Int J Hematol"},{"key":"10.1016\/j.jtct.2026.05.028_bib0010","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1182\/bloodadvances.2020002757","article-title":"Practical guidelines for monitoring and management of coagulopathy following tisagenlecleucel CAR T-cell therapy","volume":"5","author":"Buechner","year":"2021","journal-title":"Blood Adv"},{"key":"10.1016\/j.jtct.2026.05.028_bib0011","doi-asserted-by":"crossref","first-page":"4216","DOI":"10.1182\/bloodadvances.2022007454","article-title":"Relative hypercoagulation induced by suppressed fibrinolysis after tisagenlecleucel infusion in malignant lymphoma","volume":"6","author":"Yamasaki-Morita","year":"2022","journal-title":"Blood Adv"},{"key":"10.1016\/j.jtct.2026.05.028_bib0012","first-page":"2969","article-title":"Tocilizumab administration in cytokine release syndrome is associated with hypofibrinogenemia after chimeric antigen receptor T-cell therapy for hematologic malignancies","volume":"109","author":"Perl","year":"2024","journal-title":"Haematologica"},{"key":"10.1016\/j.jtct.2026.05.028_bib0013","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/s40360-024-00827-6","article-title":"Characteristics, risk factors and a risk prediction model of tocilizumab-induced hypofibrinogenemia: a retrospective real-world study of inpatients","volume":"26","author":"Cai","year":"2025","journal-title":"BMC Pharmacol Toxicol"},{"key":"10.1016\/j.jtct.2026.05.028_bib0014","doi-asserted-by":"crossref","first-page":"975","DOI":"10.21037\/atm-22-3814","article-title":"The correlation factors and prognostic significance of coagulation disorders after chimeric antigen receptor T cell therapy in hematological malignancies: a cohort study","volume":"10","author":"Dong","year":"2022","journal-title":"Ann Transl Med"},{"key":"10.1016\/j.jtct.2026.05.028_bib0015","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1016\/j.bbmt.2019.11.027","article-title":"Coagulation disorders after chimeric antigen receptor t cell therapy: analysis of 100 patients with relapsed and refractory hematologic malignancies","volume":"26","author":"Wang","year":"2020","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jtct.2026.05.028_bib0016","doi-asserted-by":"crossref","first-page":"3","DOI":"10.2991\/chi.k.210117.001","article-title":"The many faces of cytokine release syndrome-related coagulopathy","volume":"3","author":"Wang","year":"2021","journal-title":"Clin Hematol Int"},{"key":"10.1016\/j.jtct.2026.05.028_bib0017","first-page":"2430","article-title":"How I treat refractory CRS and ICANS after CAR T-cell therapy","volume":"141","author":"Jain","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2026.05.028_bib0018","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1016\/j.jtct.2024.01.073","article-title":"Clinical Impact of Cytokine Release Syndrome on Prolonged Hematotoxicity after Chimeric Antigen Receptor T Cell Therapy: KyoTox A-Score, a Novel Prediction Model","volume":"30","author":"Nakamura","year":"2024","journal-title":"Transplant Cell Ther"},{"key":"10.1016\/j.jtct.2026.05.028_bib0019","first-page":"36","article-title":"CAR T-Cell therapies in lymphoma: current landscape, ongoing investigations, and future directions","volume":"7","author":"Haydu","year":"2021","journal-title":"J Cancer Metastasis Treat"},{"key":"10.1016\/j.jtct.2026.05.028_bib0020","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1038\/nrclinonc.2017.148","article-title":"Chimeric antigen receptor T-cell therapy - assessment and management of toxicities","volume":"15","author":"Neelapu","year":"2018","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.jtct.2026.05.028_bib0021","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1111\/bjh.17662","article-title":"Hemophagocytic lymphohistiocytosis-like toxicity (carHLH) after CD19-specific CAR T-cell therapy","volume":"194","author":"Hines","year":"2021","journal-title":"Br J Haematol"},{"key":"10.1016\/j.jtct.2026.05.028_bib0022","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1056\/NEJMoa1804980","article-title":"Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma","volume":"380","author":"Schuster","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtct.2026.05.028_bib0023","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/S0140-6736(20)31366-0","article-title":"Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study","volume":"396","author":"Abramson","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.jtct.2026.05.028_bib0024","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S1470-2045(18)30864-7","article-title":"Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial","volume":"20","author":"Locke","year":"2019","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jtct.2026.05.028_bib0025","series-title":"KYMRIAH (tisagenlecleucel) prescribing information","year":"2022"},{"key":"10.1016\/j.jtct.2026.05.028_bib0026","series-title":"BREYANZI (lisocabtagene maraleucel) prescribing information","year":"2022"},{"key":"10.1016\/j.jtct.2026.05.028_bib0027","series-title":"YESCARTA (axicabtagene ciloleucel) prescribing information","author":"Kite Pharma","year":"2023"},{"key":"10.1016\/j.jtct.2026.05.028_bib0028","series-title":"Guideline for the Use of Blood Products","year":"2017"},{"issue":"3","key":"10.1016\/j.jtct.2026.05.028_bib0029","doi-asserted-by":"crossref","first-page":"525","DOI":"10.3925\/jjtc.65.525","article-title":"Guideline for the use of fresh frozen plasma based on scientific evidence (revised second version)","volume":"65","author":"Matsushita","year":"2019","journal-title":"Japanese Journal of Transfusion and Cell Therapy"},{"key":"10.1016\/j.jtct.2026.05.028_bib0030","series-title":"Goodman & Gilman\u2019s The Pharmacological Basis of Therapeutics","year":"2017"},{"key":"10.1016\/j.jtct.2026.05.028_bib0031","doi-asserted-by":"crossref","first-page":"1720","DOI":"10.1038\/s41375-022-01620-2","article-title":"The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms","volume":"36","author":"Alaggio","year":"2022","journal-title":"Leukemia"},{"key":"10.1016\/j.jtct.2026.05.028_bib0032","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1200\/JCO.2006.09.2403","article-title":"International Harmonization Project on Lymphoma. Revised response criteria for malignant lymphoma","volume":"25","author":"Cheson","year":"2007","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1016\/j.jtct.2026.05.028_bib0033","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.1002\/jha2.1043","article-title":"Fluctuation of physical function during chimeric antigen receptor T-cell therapy during rehabilitation intervention: Real-world data and risk factor analyses","volume":"5","author":"Hamada","year":"2024","journal-title":"EJHaem"},{"key":"10.1016\/j.jtct.2026.05.028_bib0034","doi-asserted-by":"crossref","first-page":"110","DOI":"10.3324\/haematol.2022.280805","article-title":"Axicabtagene ciloleucel compared to tisagenlecleucel for the treatment of aggressive B-cell lymphoma","volume":"108","author":"Kwon","year":"2023","journal-title":"Haematologica"},{"key":"10.1016\/j.jtct.2026.05.028_bib0035","doi-asserted-by":"crossref","first-page":"5571","DOI":"10.1182\/bloodadvances.2025016778","article-title":"Comparative real-world outcomes of CD19-directed CAR T-cell therapies in large B-cell lymphoma","volume":"9","author":"Desch\u00eanes-Simard","year":"2025","journal-title":"Blood Adv"},{"key":"10.1016\/j.jtct.2026.05.028_bib0036","doi-asserted-by":"crossref","first-page":"2145","DOI":"10.1038\/s41591-022-01969-y","article-title":"A real-world comparison of tisagenlecleucel and axicabtagene ciloleucel CAR T cells in relapsed or refractory diffuse large B cell lymphoma","volume":"28","author":"Bachy","year":"2022","journal-title":"Nat Med"},{"key":"10.1016\/j.jtct.2026.05.028_bib0037","doi-asserted-by":"crossref","first-page":"5729","DOI":"10.7150\/jca.99427","article-title":"Comparison of the efficacy and safety of Axi-cel and Tisa-cel based on meta-analysis","volume":"15","author":"Liao","year":"2024","journal-title":"J Cancer"},{"key":"10.1016\/j.jtct.2026.05.028_bib0038","doi-asserted-by":"crossref","first-page":"2200","DOI":"10.1080\/10428194.2025.2532674","article-title":"Matching-adjusted indirect comparison of lisocabtagene maraleucel versus axicabtagene ciloleucel for second-line treatment of patients with early relapsed or refractory large B-cell lymphoma","volume":"66","author":"Abramson","year":"2025","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.jtct.2026.05.028_bib0039","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1182\/bloodadvances.2024012992","article-title":"A real-world comparison of commercial-use axicabtagene ciloleucel and lisocabtagene maraleucel in large B-cell lymphoma","volume":"9","author":"Looka","year":"2025","journal-title":"Blood Adv"},{"key":"10.1016\/j.jtct.2026.05.028_bib0040","first-page":"2040","article-title":"Real-world comparison of lisocabtagene maraleucel and axicabtagene ciloleucel in large B-cell lymphoma: an inverse probability of treatment weighting analysis with 3-year follow-up","volume":"110","author":"Portuguese","year":"2025","journal-title":"Haematologica"},{"key":"10.1016\/j.jtct.2026.05.028_bib0041","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1160\/TH12-04-0273","article-title":"Fibrinogen gene regulation","volume":"108","author":"Fish","year":"2012","journal-title":"Thromb Haemost."},{"key":"10.1016\/j.jtct.2026.05.028_bib0042","doi-asserted-by":"crossref","first-page":"1574","DOI":"10.1053\/euhj.1999.2207","article-title":"Genetics of inflammation and risk of coronary artery disease: the central role of interleukin-6","volume":"21","author":"Woods","year":"2000","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jtct.2026.05.028_bib0043","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1056\/NEJMra2206346","article-title":"Humoral innate immunity and acute-phase proteins","volume":"388","author":"Mantovani","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtct.2026.05.028_bib0044","doi-asserted-by":"crossref","first-page":"R101","DOI":"10.1530\/EJE-15-0308","article-title":"Mechanisms in endocrinology: the spectrum of haemostatic abnormalities in glucocorticoid excess and defect","volume":"173","author":"Isidori","year":"2015","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.jtct.2026.05.028_bib0045","first-page":"1035","article-title":"How we manage a high D-dimer","volume":"109","author":"Franchini","year":"2024","journal-title":"Haematologica"},{"key":"10.1016\/j.jtct.2026.05.028_bib0046","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1515\/cclm-2017-1205","article-title":"Laboratory hemostasis: from biology to the bench","volume":"56","author":"Lippi","year":"2018","journal-title":"Clin Chem Lab Med"}],"container-title":["Transplantation and Cellular Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666636726004161?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666636726004161?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,2]],"date-time":"2026-08-02T20:11:41Z","timestamp":1785701501000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666636726004161"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":46,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["S2666636726004161"],"URL":"https:\/\/doi.org\/10.1016\/j.jtct.2026.05.028","relation":{},"ISSN":["2666-6367"],"issn-type":[{"value":"2666-6367","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Prolonged Cytokine Release Syndrome is Associated with Hypofibrinogenemia after CD19-Directed CAR T-Cell Therapy in Adult Patients with Relapsed\/Refractory Lymphoma","name":"articletitle","label":"Article Title"},{"value":"Transplantation and Cellular Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtct.2026.05.028","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Inc. on behalf of American Society for Transplantation and Cellular Therapy.","name":"copyright","label":"Copyright"}]}}